DT News - India - US FDA grants Emergency Use Authorization (EUA) for the antiviral drug Remdesivir to treat COVID-19

Rajeev Chitguppi, Dental Tribune South Asia

Sat. 2 May 2020

save

The US Food and Drug Administration has granted 'Emergency Use Authorization (EUA)' for Gilead Sciences’ antiviral drug remdesivir to treat COVID-19, the disease caused by the coronavirus. Remdesivir is now the first authorized therapy drug for COVID-19.

The experimental antiviral drug remdesivir has been approved by the US Food and Drug Administration to treat hospitalized patients with severe Covid-19.

The US FDA Commissioner Stephen Hahn said "This is an important clinical advance that showed a statistically significant reduction in time to recovery for patients with COVID-19 and is the first authorized therapy for COVID-19."

Remdesivir is a direct-acting antiviral drug that inhibits viral RNA synthesis. Remdesivir has activity in cell culture and animal models against SARS-CoV, MERS-CoV, and SARS-CoV-2.

The US FDA has stated that "Based on a review of the topline data from the randomized, double-blinded, placebo-controlled trial conducted by NIAID (NCT04280705) and from the Gilead-sponsored open-label trial that evaluated different durations of remdesivir (NCT04292899), it is reasonable to believe that the known and potential benefits of RDV outweigh the known and potential risks of the drug for the treatment of patients hospitalized with severe COVID-19."

Download the US FDA document by clicking here

The 'Emergency Use Authorization (EUA)' for remdesivir means that the drug remdesivir has not undergone the same level of review as an FDA-approved treatment.

The EUA letter says "Remdesivir is an investigational antiviral medicine to treat certain people in the hospital with COVID-19. Remdesivir is investigational because it is still being studied. There is limited information known about the safety and effectiveness of using remdesivir to treat people in the hospital with COVID-19. Remdesivir was shown in a clinical trial to shorten the time to recovery in some people."

Download the EUA of remdesivir for the coronavirus disease (COVID- 19)

However, doctors will be allowed to use remdesivir on patients hospitalized with the disease, even though the drug has not been formally approved by the agency.

The company Gilead Sciences has also released the preliminary results from its own study, which shows improvement in at least 50% of the patients treated with a five-day course of remidesivir. The clinical trial was a single-arm study without a control (no -treatment) group. The trial had recruited 397 severe cases of COVID-19.

Tags:

To post a reply please login or register

WHO rejects remdesivir for COVID-19

The World Health Organization (WHO) panel, in its latest statement, has recommended against the use of the remdesivir, an antiviral drug, in hospitalized ...

ICMR replies to dentist's letter on the use of Rapid Antigen Tests for Covid-19 in dental clinics

Rapid Antigen Tests are an easy and economical option for dentists to use in their clinics to identify the potential Covid-19 spreaders visiting their ...

‘Mask Mouth’- a novel threat to oral health in the COVID era - Dr Pooja Muley

Today the use of face masks has become necessary and ubiquitous due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Even ...

US visas in 2025 – What you should know and why the US is still the #1 destination for international dentists

The founders of Dental Window, India’s only career consultancy focused exclusively on overseas dentistry, note that despite the current geopolitical noise...

How COVID-19 has forced us all to relook our practices, lives and goals

Many of us react in quite different ways to changes happening around us. Take a moment to read this short account of what is not so much my change journey, ...

How to make use of Antigen Tests for Covid-19? How do antigen tests differ from RT PCR?

This article aims to remove all the existing confusions on Covid-19 antigen tests. Also, explains the difference between the results obtained from antigen ...

Breakthrough COVID-19 infections among the vaccinated may not be a severe threat

As the COVID-19 vaccination drive continues to expand throughout the world, SARS-CoV-2 variant mutations and breakthrough infections have posed a new public...

It’s time we used Vitamin D to reduce the risk of COVID-19 severity

People that traditionally exhibit vitamin D deficiency, such as older adults and nursing home residents, are the same groups that have also been excessively...